Sparks commentary

Healthcare

Sparks

FDA approves Vertex’s (NASDAQ: VRTX) pain drug
Published by Arron Aatkar, PhD

The US FDA has approved Vertex’s suzetrigine, now called Journavx, for the treatment of adults with moderate-to-severe acute pain. Vertex has spent many decades in the challenging field of pain management and the approval of  Journavx represents a significant milestone in public health, especially following the opioid epidemic in the US.

 

Latest

Consumer | Comment

Aston Martin posts £112m Q3 loss

Financials | Comment

Barclays (LON:BARC) Q3 results show momentum

TMT | Comment

XP Power (LSE:XPP) reports inline Q3 trading update